Enterprise Value

1.698B

Cash

854.8M

Avg Qtr Burn

-97.73M

Short % of Float

12.43%

Insider Ownership

1.09%

Institutional Own.

93.89%

Qtr Updated

09/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
NTLA-2001 (CRISPR/Cas9) Details
Hereditary transthyretin amyloidosis, Polyneuropathy

Phase 3

Initiation

NTLA-2001 (CRISPR/Cas9) Details
Transthyretin amyloidosis, Transthyretin Amyloid Cardiomyopathy, Cardiomyopathy

Phase 3

Initiation

NTLA-2002 (KLKB1 Inhibitor) Details
Hereditary angioedema , Rare genetic disease, Rare diseases

Phase 1/2

Data readout

NTLA-5001 Details
Acute myeloid leukemia

Failed

Discontinued

Failed

Discontinued